Rapid risk assessment: Carbapenem-resistant Acinetobacter baumannii in healthcare settings – 8 December 2016
Carbapenem-resistant A. baumannii poses a significant threat to patients and healthcare systems. A. baumannii is the cause of serious infections in healthcare settings. The situation is exacerbated by the bacteria’s carbapenem resistance which limits treatment options and increases the risk for adverse outcomes. This risk assessment provides an overview of the epidemiological situation in Europe and describes a number of response options.
Acinetobacter baumannii is the cause of difficult-to-treat infections in healthcare settings in Europe due to its increasing resistance to antimicrobial agents, in particular the carbapenems. Outbreaks of carbapenem-resistant A. baumannii in healthcare facilities have been reported in Europe and worldwide.
Infections with carbapenem-resistant A. baumannii occur in patients with severe underlying diseases, mainly in intensive care units, and are often related to invasive procedures or indwelling devices. However, such infections are increasingly being reported in patients admitted to conventional medical and surgical wards. A. baumannii is difficult to eradicate once it has become endemic.
Recent ECDC data from the European survey on carbapenemase-producing Enterobacteriaceae (EuSCAPE) project and from the European Antimicrobial Resistance Surveillance Network (EARS-Net) confirmed that although there is already a high resistance baseline in some countries, there has been an overall increase of carbapenem-resistant A. baumannii in Europe.
These data confirm an already alarming situation that continues to worsen in many EU/EEA countries. While carbapenems traditionally were the antibiotics of choice for treatment of A. baumannii infections, resistance to these drugs has led to increased use of colistin as last-line treatment. Although still rare, resistance to colistin in A. baumannii is also increasingly being reported in Europe.
This risk assessment highlights the need of increased efforts to face this significant threat to patients and healthcare systems in all EU/EEA countries and outlines options to reduce risks through clinical management, prevention of transmission in hospitals and other healthcare settings, prevention of cross-border transmission, and improvement of preparedness of EU/EEA countries.
Rapid risk assessment: Increase in OXA -244 -producing Escherichia coli in the European Union/European Economic Area and the UK since 2013
18 Feb 2020 - Rapid risk/outbreaks assessment aim at supporting the countries and the European Commission in their preparedness and response to a public health threat. They provide a timely summary and risk assessment of a public health threat for EU/EEA countries related to a specific event. They also include potential options for response. As outbreaks or public health events develop, ECDC may issue updated risk assessments.
Combined clonal and plasmid-mediated outbreak of carbapenemase-producing Enterobacterales, Lithuania, 2019–2020
3 Feb 2020 - Combined clonal and plasmid-mediated outbreak of carbapenemase-producing Enterobacterales, Lithuania, 2019–2020
Rapid risk assessment: Outbreak of carbapenemase-producing Enterobacterales in Lithuania, 2019
18 Dec 2019 - Between 1st February and 26th November 2019, 199 cases of Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant Enterobacterales (KPC-CRE) have been detected in Lithuania.